Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-TKI for nAMD
NCT04989699Phase 1Completed
- Sponsor
- Ocular Therapeutix
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of axitinib intravitreal implant in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Ocular Therapeutix. Primary endpoint: Safety and Tolerability at 1 year. Started Jul 2021; status: completed.
02
Drugs
axitinib intravitreal implant
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04989699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989699.